Scarica il documento in formato pdf (574 KB - ANCE

and Hispanic origin: (Updated 11/2002).
Data from Centers for Disease Control and
Prevention, National Center for Health Statistics,
National Health and Nutrition Examination
Survey, Hispanic Health and Nutrition
Examination Survey and National
Health Examination Survey
5. Mancia G. Lo studio ALLHAT: contributi, limiti
e prospettive. Ital Heart J Suppl 2003;
4 (2): 77-84
6. Laragh JH, Sealey JE. Relevance of the plasma
renin hormonal control system that regulates
blood pressure and sodium balance
for correctly treating hypertension and for
evaluating ALLHAT. Am J Hypertens 2003
May; 16(5):407-415
7. Meltzer JI. A specialist in clinical hypertension
critiques ALLHAT. Am J Hypertens
2003 May; 16(5):416-420
8. Wing LMH, Reid CM, Ryan PA et al. Comparison
of Outcomes with Angiotensin-
Converting-Enzyme Inhibitors and Diuretics
for Hypertension in the Elderly. N Engl
J Med 2003; 348(7): 583-592
9. Medical Research Council Working Party.
Medical Research Council trial of treatment
of hypertension in older adults: principal results.
BMJ 1992;304:405-412
10. SHEP Cooperative Research Group. Prevention
of stroke by antihypertensive drug
treatment in older persons with isolated
systolic hypertension: final results of the
Systolic Hypertension in the Elderly Program
(SHEP). JAMA 1991;265:3255-3264
11. Dahlof B, Lindholm LH, Hansson L et al.
Morbidity and mortality in the Swedish Trial
in Old Patients with Hypertension (STOP-
Hypertension). Lancet 1991;338:1281-1285
12. Dahlof B, Pennert K, Hansson L. Reversal of
left ventricular hypertrophy in hypertensive
patients: a metaanalysis of 109 treatment
studies. Am J Hypertens 1992;5:95-110.
13. Dahlof B, Devereux RB, Kjeldsen SE et al.
Cardiovascular morbidity and mortality in
the Losartan Intervention for Endpoint reduction
in hypertension study (LIFE): a randomised
trial against atenolol. Lancet
2002;359:995-1003.
14. Hypertension Detection and Follow-up Program.
The effect of treatment on mortality
in ‘mild’ hypertension: results of the Hypertension
Detection and Follow-up Program.
N Engl J Med 1982; 307:976–980
15. Zanchetti A, Hansson L, Menard J et al.
Risk assessment and treatment benefit in
intensively treated hypertensive patients of
the Hypertension Optimal Treatment
(HOT) study for the HOT Study Group. J
Hypertens 2001; 19:819–825
16. Levy D, Salomon M, D’Agostino RB et al.
Prognostic implications of baseline electrocardiographic
features and their serial changes
in subjects with left ventricular hyper-
trophy. Circulation 1994; 90:1786–1793
17. Mathew J, Sleight P, Lonn E et al. Reduction
of cardiovascular risk by regression of
electrocardiographic markers of left ventricular
hypertrophy by the angiotensin-converting
enzyme inhibitor ramipril. Circulation
2001; 104:1615–1621
18. Hansson L, Lindholm LH, Niskanen L et al.
Effect of angiotensin-converting-enzyme inhibition
compared with conventional therapy
on cardiovascular morbidity and mortality
in hypertension: the Captopril Prevention
Project (CAPPP) randomised trial. Lancet
1999;353:611-616.
19. Cook NR, Cohen J, Hekbert PR et al. Implications
of small reductions in diastolic
blood pressure for primary prevention.
Arch Intern Med 1995; 155: 701–09.
20. Vasan RS, Beiser A, Seshadri S et al. Residual
lifefetime risk for developing hyeprtension
in middle-aged women and men:
The Framingham Heart Study. JAMA 2002;
287: 1003-1010
21. Guidelines Committee - 2003 European
Society of Hypertension–European Society
of Cardiology guidelines for the management
of arterial hypertension. Journal of
Hypertension 2003, 21:1011–1053
22. Terpstra WL, May JF, Smit AJ et al. Longterm
effects of amlodipine and lisinopril on
left ventricular mass and diastolic function
in elderly, previously untreated hypertensive
patients: the ELVERA trial. J Hypertens
2001; 19:303–309
23. Devereux RB, Palmieri V, Sharpe N et al.
Effects of once-daily angiotensin-converting
enzyme inhibition and calcium channel
blockade-based antihypertensive treatment
regimens on left ventricular hypertrophy
and diastolic filling in hypertension. The
Prospective Randomized Enalapril Study
Evaluating Regression of Ventricular Enlargement
(PRESERVE) trial. Circulation 2001;
104:1248–1254
24. Thurmann PA, Kenedi P, Schmidt A et al.
Influence of the angiotensin II antagonist
valsartan on left ventricular hypertrophy in
patients with essential hypertension. Circulation
1998; 98:2037–2042
25. Malmqvist K, Kahan T, Edner M et al. Regression
of left ventricular hypertrophy in
human hypertension with irbesartan. J
Hypertens 2001; 19:1167–1176
26. Dahlof B, Zanchetti A, Diez J et al. Effects of
losartan and atenolol on left ventricular
mass and neurohormonal profile in patients
with essential hypertension and left ventricular
hypertrophy. J Hypertens 2002;
20:1855–1864
27. Lithell H, Hansson L, Skogg I et al. for the
SCOPE Study Group. The Study on Cognition
and Prognosis in the Elderly (SCOPE).
Principalresults of a randomised double-
S. Lino
Ipertensione arteriosa
39